Results 131 to 140 of about 19,412 (203)

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study. [PDF]

Clin Cancer Res
Yu HA, Tang KH, Markovets A, Hartmaier R, Smith PE, Cho BC, De Langen AJ, Goldberg SB, Goldman JW, Le X, Iwama E, Cosaert J, Riess JW, Piotrowska Z.   +13 more
europepmc   +1 more source

Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma. [PDF]

Front Genet
Cui K, Zhu R, Li J.
europepmc   +1 more source

Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database. [PDF]

ESMO Open
Farinea G, Mogavero A, Vitale A, Roca E, Scotti V, Delmonte A, Veccia A, Reale ML, Bironzo P, Genova C, Galetta D, Bulotta A, Grossi F, Cortinovis D, Novello S, Bria E, Passiglia F.   +16 more
europepmc   +1 more source

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report

HER2 mutations have been identified as potential mechanisms of resistance to EGFR-directed therapies in patients with advanced or metastatic NSCLC. Here, we report the case of a 65-year-old female with metastatic, EGFR exon 19–mutant NSCLC initially ...
Hailey M. Hirata, PharmD, Kevin Y. Chen, PharmD, MS, Carrie B. Lee, MD, MPH   +2 more
core   +1 more source

Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer. [PDF]

Front Cell Dev Biol
A-Lai GH, Li L, Ma G, Zhao YS, Yao P, Lin YD.   +5 more
europepmc   +1 more source

Risk-adapted first-line therapy selection in advanced EGFR-mutant NSCLC: a practical clinical algorithm integrating tumor biology and patient factors. [PDF]

Med Oncol
Sharma A, Tan JK, Kumar H, Bharadwaj HR.
europepmc   +1 more source

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

J Egypt Natl Canc Inst
Mahato S, Mudgal S, Singh H, Varikasuvu SR, Kumar H, Thankachan J, Kumar S.   +6 more
europepmc   +1 more source

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives. [PDF]

Curr Oncol
Daaboul N, Agulnik JS, Bahig H, Blais N, Boucher MÈ, Bouchard N, Denault MH, Desmeules P, Fiset PO, Florescu M, Jao K, Labbé C, Lecavalier-Barsoum M, Pepe C, Shieh B, Stock-Martineau S, Marcoux N.   +16 more
europepmc   +1 more source

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study. [PDF]

Oncologist
Yang X, Tan Q, Chen S, Xie J, Zeng Y, Zheng R, Tan Q, Zhang W, Yu C, Hong Z, Yu X, Jiang G.   +11 more
europepmc   +1 more source

Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China. [PDF]

Ther Adv Med Oncol
Guo Y, Liu S, Yang C, Wang C, Zhang R, Wang Y, Song Y, Liu M, Zhang R, Xuan T, Zhao W, Li J.   +11 more
europepmc   +1 more source